NCT06924021 Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
| NCT ID | NCT06924021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Age-Related Macular Degeneration |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-05-12 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-05-12 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Eligibility Criteria
Inclusion Criteria: * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form * Willing to comply with all study procedures and sign the Informed Consent Form (ICF) * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center. Exclusion Criteria: * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed. * Unable to acquire adequate quality images, as evaluated by the Central Reading Center * Severe vision loss requiring urgent surgery * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study * Unwilling to sign informed consent form * Currently or previously enrolled in an interventional AMD clinical trial
Contact & Investigator
Amitha Domalpally, MD, PhD
PRINCIPAL INVESTIGATOR
UW School of Medicine and Public Health
Frequently Asked Questions
Who can join the NCT06924021 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Age-Related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06924021 currently recruiting?
Yes, NCT06924021 is actively recruiting participants. Contact the research team at wrc.support@wisc.edu for enrollment information.
Where is the NCT06924021 trial being conducted?
This trial is being conducted at Fargo, United States, Erie, United States, Dallas, United States, McAllen, United States and 10 additional locations.
Who is sponsoring the NCT06924021 clinical trial?
NCT06924021 is sponsored by University of Wisconsin, Madison. The principal investigator is Amitha Domalpally, MD, PhD at UW School of Medicine and Public Health. The trial plans to enroll 1,000 participants.